Lin Hong-Sheng, Li Dao-Rui
Department of Medical Oncology, Guanganmen Hospital, China Academy of Chinese Traditional Medicine, Beijing 100053, China.
Zhonghua Zhong Liu Za Zhi. 2007 Dec;29(12):931-4.
To investigate the effect of Shenqi-fuzheng injection combined with chemotherapy on the quality of life in lung cancer patient.
232 pathologically confirmed nonsmall cell lung cancer patients were enrolled into this multi-center randomized trial. Of these 232 patients, 116 cases were treated with chemotherapy alone (chemotherapy group), another 116 with chemotherapy combined with Shenqi-fuzheng injection produced by Lizhu Company (Shenqi-fuzheng group). Life quality of these patients were evaluated using the QOL scale of European Organization for Research on Treatment of Cancer (QLQ-C30) and the functional living index-cancer.
Compared with chemotherapy group, Life quality and symptoms were improved in the Shenqi-fuzheng group, which including lassitude, deficient in breath, pain, fullness in chest and hypochondrium, excessive phlegm, cough, complexion whiteness. Response rate to chemotherapy was also improved. No AE and SAE were observed in the Shenqi-fuzheng group.
Shenqi-fuzheng injection combined with chemotherapy is safe and effective in the treatment for non-small cell lung cancer.
探讨参芪扶正注射液联合化疗对肺癌患者生活质量的影响。
232例经病理确诊的非小细胞肺癌患者纳入该多中心随机试验。这232例患者中，116例仅接受化疗（化疗组），另外116例接受丽珠公司生产的参芪扶正注射液联合化疗（参芪扶正组）。使用欧洲癌症研究与治疗组织的生活质量量表（QLQ-C30）和癌症功能生活指数对这些患者的生活质量进行评估。
与化疗组相比，参芪扶正组的生活质量和症状得到改善，包括乏力、气短、疼痛、胸胁胀满、痰多、咳嗽、面色苍白。化疗缓解率也有所提高。参芪扶正组未观察到任何不良反应和严重不良反应。
参芪扶正注射液联合化疗治疗非小细胞肺癌安全有效。
